Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: GRAL

GRAIL, Inc.

Healthcare | Medical - Diagnostics & Research

No licensed closing price on file for GRAL. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-9.68

GRAIL, Inc. (NASDAQ: GRAL) is a diagnostics and research company. Figures from SEC EDGAR; updated 2026-10-20 16:48 UTC.

What GRAIL, Inc. does

The company is a healthcare organization developing Galleri, a blood test designed to detect multiple types of cancer early from a single sample by identifying specific DNA patterns in the bloodstream. Galleri can identify which organ or tissue type is affected when cancer signals are detected and has been studied in large clinical programs involving hundreds of thousands of participants.

Summarized from GRAIL, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-9.68

Revenue, margins & earnings

FY2022: net loss $5.40B on revenue $56M$56MFY2022FY2023: net loss $1.47B on revenue $93M$93MFY2023FY2024: net loss $2.03B on revenue $126M$126MFY2024FY2025: net loss $408M on revenue $147M$147MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-16
  • 2026-10-16Chief Executive OfficerSale-400$53.2K
  • 2026-10-16Chief Executive OfficerSale-2,114$293.4K
  • 2026-10-16DirectorAward237$32.1K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does GRAIL, Inc. do?

The company is a healthcare organization developing Galleri, a blood test designed to detect multiple types of cancer early from a single sample by identifying specific DNA patterns in the bloodstream.

When did GRAL last file with the SEC?

GRAIL, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-22. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 16:48 UTC. This page is also available as JSON at /api/data?ticker=GRAL and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for GRAL and 5,000+ tickers.

Create a free account — keep GRAL
For your agent
GET /api/data?ticker=GRAL

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt